SABCS

Novel Drug Has Potential to ‘Become New Standard of Care’ in Advanced, ER-Positive Breast Cancer

December 8th 2021, 2:00pm

Article

The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

Novel Drug Combo Doubles Progression-Free Survival in HER2-Negative Metastatic Breast Cancer

December 7th 2021, 10:00pm

Article

Ibrance plus Faslodex improved progression-free survival in certain patients with metastatic breast cancer, compared with those who continued to receive an aromatase inhibitor.

Black Women With Breast Cancer Have a Higher Risk of Developing Lymphedema Than White Women

December 7th 2021, 4:00pm

Article

Black race is associated with a 3.5-fold increased incidence of lymphedema in women with breast cancer treated with axillary lymph node dissection and radiotherapy, according to recent data.

Keytruda and Chemotherapy Combination Broadens Number of Treatable Patients with TNBC

January 8th 2021, 10:00pm

Article

In an interview with CURE®, lead study investigator of the Keynote 355 trial, Dr. Hope S Rugo, discusses the results of the study that led to the FDA approval of the combination therapy and what further data means for certain patients with metastatic triple-negative breast cancer.

Novel Therapy Continues to Show Prolonged, Durable Responses and Survival Outcomes in Patients with HER2-Positive Metastatic Breast Cancer

December 17th 2020, 10:00pm

Article

Updated data from the phase 2 DESTINY-Breast01 study continues to show encouraging and durable responses for patients with HER2-positive metastatic breast cancer.

Patients Who Experienced Chemotherapy-Induced Nausea/Vomiting During First Cycle of Cancer Treatment May Be at Greater Risk for Recurrence of the Side Effect

December 12th 2020, 7:00pm

Article

Approximately half of the patients with breast cancer who failed anti-nausea or vomiting therapy for chemotherapy-induced nausea/vomiting during their first cycle of treatment failed to avoid the side effect at some point during the next three treatment cycles.

Tesetaxel with Reduced Dose of Xeloda Improves Progression-Free Survival in Breast Cancer

December 12th 2020, 4:00pm

Article

Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.

Chemotherapy With Endocrine Therapy Shows Clinical Benefit With Improved Survival in Breast Cancer

December 12th 2020, 2:00pm

Article

Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.

Side Effects from Oral Paclitaxel Plus Encequidar May Be Mitigated with Anti-Nausea Medications, Loperamide

December 11th 2020, 9:30pm

Article

An increase in gastrointestinal side effects were found with the more effective combination of oral paclitaxel and encequidar; however, new safety evaluations demonstrated that various antiemetics can help treat these effects in patients with metastatic breast cancer.

Verzenio Continues to Show Reduced Risk in Invasive Disease-Free Survival in High-Risk Early HR+ Breast Cancer

December 11th 2020, 7:30pm

Article

In this phase 3 trial, Verzenio with endocrine therapy reduced the risk for invasive disease recurrence and death versus endocrine therapy alone for patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.